Cited by 298

The DOI matches its Crossref record; 217 of the 217 references it cites were found in a registry or an index.

Paclitaxel: Application in Modern Oncology and Nanomedicine‐Based Cancer Therapy

Open access

Sharifi-Rad, Javad, Quispe, Cristina, Patra, Jayanta Kumar, Singh, Yengkhom Disco, Panda, Manasa Kumar, Das, Gitishree, Adetunji, Charles Oluwaseun, Michael, Olugbenga Samuel, Sytar, Oksana, Polito, Letizia, Živković, Jelena, Cruz-Martins, Natália, Klimek-Szczykutowicz, Marta, Ekiert, Halina, Choudhary, Muhammad Iqbal, Ayatollahi, Seyed Abdulmajid, Tynybekov, Bekzat, Kobarfard, Farzad, Muntean, Ana Covilca, Grozea, Ioana, Daştan, Sevgi Durna, Butnariu, Monica, Szopa, Agnieszka, Calina, Daniela·2021·Oxidative Medicine and Cellular Longevity

DOI 10.1155/2021/3687700

Open this paper in CoChat — free account

Abstract

Paclitaxel is a broad‐spectrum anticancer compound, which was derived mainly from a medicinal plant, in particular, from the bark of the yew tree Taxus brevifolia Nutt. It is a representative of a class of diterpene taxanes, which are nowadays used as the most common chemotherapeutic agent against many forms of cancer. It possesses scientifically proven anticancer activity against, e.g., ovarian, lung, and breast cancers. The application of this compound is difficult because of limited solubility, recrystalization upon dilution, and cosolvent‐induced toxicity. In these cases, nanotechnology and nanoparticles provide certain advantages such as increased drug half‐life, lowered toxicity, and specific and selective delivery over free drugs. Nanodrugs possess the capability to buildup in the tissue which might be linked to enhanced permeability and retention as well as enhanced antitumour influence possessing minimal toxicity in normal tissues. This article presents information about paclitaxel, its chemical structure, formulations, mechanism of action, and toxicity. Attention is drawn on nanotechnology, the usefulness of nanoparticles containing paclitaxel, its opportunities, and also future perspective. This review article is aimed at summarizing the current state of continuous pharmaceutical development and employment of nanotechnology in the enhancement of the pharmacokinetic and pharmacodynamic features of paclitaxel as a chemotherapeutic agent.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1155/2021/3687700

Cites

217 of 217 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Cancer statistics, 2016
Siegel, R. L., Miller, K. D., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21332 · Cited by 16,003 · cited 1×
“The mortality of cancer is reported more in men than in women, especially for lung, colorectal, and stomach cancers [171, 172].”
Background
Cancer-related inflammation
Mantovani, A., Allavena, P., Sica, A., & Balkwill, F. (2008) · Nature · doi:10.1038/nature07205 · Cited by 11,399
Immunity, Inflammation, and Cancer
Grivennikov, S. I., Greten, F. R., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2010.01.025 · Cited by 10,755
Natural Products as Sources of New Drugs over the Nearly Four Decades from 01/1981 to 09/2019
Newman, D. J., & Cragg, G. M. (2020) · Journal of Natural Products · doi:10.1021/acs.jnatprod.9b01285 · Cited by 7,015
A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs.
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
Maeda, H., Wu, J., Sawa, T., Matsumura, Y., & Hori, K. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00248-5 · Cited by 6,565
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474
Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study
Global Burden of Disease Cancer Collaboration, Fitzmaurice, C., Allen, C., Barber, R. M., Barregard, L., Bhutta, Z. A., Brenner, H., Dicker, D. J., Chimed-Orchir, O., Dandona, R., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.5688 · Cited by 6,215
Natural products in drug discovery: advances and opportunities
Atanasov, A. G., Zotchev, S. B., Dirsch, V. M., Taskforce, T. I. N. P. S., Orhan, I. E., Banach, M., Rollinger, J. M., Barreca, D., Weckwerth, W., Bauer, R., et al. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-00114-z · Cited by 5,392
STATs in cancer inflammation and immunity: a leading role for STAT3
Yu, H., Pardoll, D., & Jove, R. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2734 · Cited by 4,383
Microtubules as a target for anticancer drugs
Jordan, M. A., & Wilson, L. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1317 · Cited by 4,000
The Causes of Cancer: Quantitative Estimates of Avoidable Risks of Cancer in the United States Today
Doll, R., & Peto, R. (1981) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/66.6.1192 · Cited by 3,927 · cited 1×
“Infectious disease and parasitic disease claimed 10% of the population of cancer patients in the US [191], 10-20% in the UK, 3.”
Background
Targeting multidrug resistance in cancer
Szakács, G., Paterson, J. K., Ludwig, J. A., Booth-Genthe, C., & Gottesman, M. M. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1984 · Cited by 3,609
Promotion of microtubule assembly in vitro by taxol
SCHIFF, P. B., FANT, J., & HORWITZ, S. B. (1979) · Nature · doi:10.1038/277665a0 · Cited by 3,600
The Causes of Cancer: Quantitative Estimates of Avoidable Risks of Cancer in the United States Today
Peto, R. (1983) · The Use of Human Cells for the Evaluation of Risk from Physical and Chemical Agents · doi:10.1007/978-1-4757-1117-2_30 · Cited by 3,501
NF-κB: linking inflammation and immunity to cancer development and progression
Karin, M., & Greten, F. R. (2005) · Nature Reviews Immunology · doi:10.1038/nri1703 · Cited by 3,085
The Three Es of Cancer Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104803 · Cited by 3,072
The global health burden of infection‐associated cancers in the year 2002
Parkin, D. M. (2006) · International Journal of Cancer · doi:10.1002/ijc.21731 · Cited by 2,932
MICROTUBULE POLYMERIZATION DYNAMICS
Desai, A., & Mitchison, T. J. (1997) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.13.1.83 · Cited by 2,563
Global burden of cancers attributable to infections in 2008: a review and synthetic analysis
de Martel, C., Ferlay, J., Franceschi, S., Vignat, J., Bray, F., Forman, D., & Plummer, M. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70137-7 · Cited by 2,534
IKKβ Links Inflammation and Tumorigenesis in a Mouse Model of Colitis-Associated Cancer
Greten, F. R., Eckmann, L., Greten, T. F., Park, J. M., Li, Z.-W., Egan, L. J., Kagnoff, M. F., & Karin, M. (2004) · Cell · doi:10.1016/j.cell.2004.07.013 · Cited by 2,433
Intestinal inflammation targets cancer-inducing activity of the microbiota
Arthur, J. C., Perez-Chanona, E., Mühlbauer, M., Tomkovich, S., Uronis, J. M., Fan, T.-J., Campbell, B. J., Abujamel, T., Dogan, B., Rogers, A. B., et al. (2012) · Science · doi:10.1126/science.1224820 · Cited by 2,263
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
Sun, T., Zhang, Y. S., Pang, B., Hyun, D. C., Yang, M., & Xia, Y. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201403036 · Cited by 2,164
Antibody therapy of cancer
Scott, A. M., Wolchok, J. D., & Old, L. J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3236 · Cited by 2,160
IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer
Grivennikov, S., Karin, E., Terzic, J., Mucida, D., Yu, G.-Y., Vallabhapurapu, S., Scheller, J., Rose-John, S., Cheroutre, H., Eckmann, L., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.001 · Cited by 2,155
Chemotherapy and the war on cancer
Chabner, B. A., & Roberts, T. G. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1529 · Cited by 2,154
Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil–Based Paclitaxel in Women With Breast Cancer
Gradishar, W. J., Tjulandin, S., Davidson, N., Shaw, H., Desai, N., Bhar, P., Hawkins, M., & O'Shaughnessy, J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.937 · Cited by 2,153
Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study
Ozols, R. F., Bundy, B. N., Greer, B. E., Fowler, J. M., Clarke-Pearson, D., Burger, R. A., Mannel, R. S., DeGeest, K., Hartenbach, E. M., & Baergen, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.02.153 · Cited by 2,032
Lifestyle, oxidative stress, and antioxidants: Back and forth in the pathophysiology of chronic diseases
Sharifi-Rad, M., Anil Kumar, N. V., Zucca, P., Varoni, E. M., Dini, L., Panzarini, E., Rajkovic, J., Tsouh Fokou, P. V., Azzini, E., Peluso, I., et al. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00694 · Cited by 1,971 · cited 2×
“Factors that can predispose to cancer include environmental factors that can cause some or all of the chronic inflammation, sometimes of low intensity [118].”
BackgroundSelf-citation
Taxol stabilizes microtubules in mouse fibroblast cells.
Schiff, P. B., & Horwitz, S. B. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.3.1561 · Cited by 1,970
Paclitaxel (Taxol)
Rowinsky, E. K., & Donehower, R. C. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504133321507 · Cited by 1,924
Radical causes of cancer
Hussain, S. P., Hofseth, L. J., & Harris, C. C. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1046 · Cited by 1,690
Cremophor EL
Gelderblom, H., Verweij, J., Nooter, K., & Sparreboom, A. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00171-x · Cited by 1,655
Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors
Din, F. U., Aman, W., Ullah, I., Qureshi, O. S., Mustapha, O., Shafique, S., & Zeb, A. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s146315 · Cited by 1,577
Neutrophil extracellular traps produced during inflammation awaken dormant cancer cells in mice
Albrengues, J., Shields, M. A., Ng, D., Park, C. G., Ambrico, A., Poindexter, M. E., Upadhyay, P., Uyeminami, D. L., Pommier, A., Küttner, V., et al. (2018) · Science · doi:10.1126/science.aao4227 · Cited by 1,476
p53 Status and the Efficacy of Cancer Therapy in Vivo
Lowe, S. W., Bodis, S., McClatchey, A., Remington, L., Ruley, H. E., Fisher, D. E., Housman, D. E., & Jacks, T. (1994) · Science · doi:10.1126/science.7973635 · Cited by 1,469
Paul Ehrlich's magic bullet concept: 100 years of progress
Strebhardt, K., & Ullrich, A. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2394 · Cited by 1,457
The atlas of heart disease and stroke
Beevers, D. G. (2005) · Journal of Human Hypertension · doi:10.1038/sj.jhh.1001852 · Cited by 1,247
Taxol: A Unique Antineoplastic Agent with Significant Activity in Advanced Ovarian Epithelial Neoplasms
McGuire, W. P., Rowinsky, E. K., Rosenshein, N. B., Grumbine, F. C., Ettinger, D. S., Armstrong, D. K., & Donehower, R. C. (1989) · Annals of Internal Medicine · doi:10.7326/0003-4819-111-4-273 · Cited by 1,100
Paclitaxel and its formulations
Singla, A. K., Garg, A., & Aggarwal, D. (2002) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(01)00986-3 · Cited by 1,100
Intestinal Tumorigenesis Initiated by Dedifferentiation and Acquisition of Stem-Cell-like Properties
Schwitalla, S., Fingerle, A. A., Cammareri, P., Nebelsiek, T., Göktuna, S. I., Ziegler, P. K., Canli, O., Heijmans, J., Huels, D. J., Moreaux, G., et al. (2013) · Cell · doi:10.1016/j.cell.2012.12.012 · Cited by 1,068
Bovine milk-derived exosomes for drug delivery
Munagala, R., Aqil, F., Jeyabalan, J., & Gupta, R. C. (2016) · Cancer Letters · doi:10.1016/j.canlet.2015.10.020 · Cited by 931
Improving the efficacy of antibody-based cancer therapies
Carter, P. (2001) · Nature Reviews Cancer · doi:10.1038/35101072 · Cited by 833
Blocking TNF-α in mice reduces colorectal carcinogenesis associated with chronic colitis
Popivanova, B. K., Kitamura, K., Wu, Y., Kondo, T., Kagaya, T., Kaneko, S., Oshima, M., Fujii, C., & Mukaida, N. (2008) · Journal of Clinical Investigation · doi:10.1172/jci32453 · Cited by 832
Abnormal Centrosome Amplification in the Absence of p53
Fukasawa, K., Choi, T., Kuriyama, R., Rulong, S., & Woude, G. F. V. (1996) · Science · doi:10.1126/science.271.5256.1744 · Cited by 797
TGF-β Suppresses Tumor Progression in Colon Cancer by Inhibition of IL-6 trans-Signaling
Becker, C., Fantini, M. C., Schramm, C., Lehr, H. A., Wirtz, S., Nikolaev, A., Burg, J., Strand, S., Kiesslich, R., Huber, S., et al. (2004) · Immunity · doi:10.1016/j.immuni.2004.07.020 · Cited by 726
IL-22BP is regulated by the inflammasome and modulates tumorigenesis in the intestine
Huber, S., Gagliani, N., Zenewicz, L. A., Huber, F. J., Bosurgi, L., Hu, B., Hedl, M., Zhang, W., O’Connor, W., Murphy, A. J., et al. (2012) · Nature · doi:10.1038/nature11535 · Cited by 719
Nutrition and cancer: A review of the evidence for an anti-cancer diet
Donaldson, M. S. (2004) · Nutrition Journal · doi:10.1186/1475-2891-3-19 · Cited by 699
Alcohol drinking and colorectal cancer risk: an overall and dose–response meta-analysis of published studies
Fedirko, V., Tramacere, I., Bagnardi, V., Rota, M., Scotti, L., Islami, F., Negri, E., Straif, K., Romieu, I., La Vecchia, C., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq653 · Cited by 682
Paclitaxel-resistant Human Ovarian Cancer Cells Have Mutant β-Tubulins That Exhibit Impaired Paclitaxel-driven Polymerization
Giannakakou, P., Sackett, D. L., Kang, Y.-K., Zhan, Z., Buters, J. T. M., Fojo, T., & Poruchynsky, M. S. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.27.17118 · Cited by 681
The microtubule-affecting drug paclitaxel has antiangiogenic activity.
Belotti, D., Vergani, V., Drudis, T., Borsotti, P., Pitelli, M. R., Viale, G., Giavazzi, R., & Taraboletti, G. (1996) · PubMed · Cited by 643
Taxol binds to polymerized tubulin in vitro
Parness, J., & Horwitz, S. (1981) · The Journal of Cell Biology · doi:10.1083/jcb.91.2.479 · Cited by 620
A Clear, Strong, and Thermally Insulated Transparent Wood for Energy Efficient Windows
Mi, R., Li, T., Dalgo, D., Chen, C., Kuang, Y., He, S., Zhao, X., Xie, W., Gan, W., Zhu, J., et al. (2020) · Advanced Functional Materials · doi:10.1002/adfm.201907511 · Cited by 619
Inorganic nanoparticles for cancer imaging and therapy
Huang, H.-C., Barua, S., Sharma, G., Dey, S. K., & Rege, K. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.06.004 · Cited by 618
Paclitaxel Nano-Delivery Systems: A Comprehensive Review
Ma, P. (2013) · Journal of Nanomedicine & Nanotechnology · doi:10.4172/2157-7439.1000164 · Cited by 559
DNA damage induced by chronic inflammation contributes to colon carcinogenesis in mice
Meira, L. B., Bugni, J. M., Green, S. L., Lee, C.-W., Pang, B., Borenshtein, D., Rickman, B. H., Rogers, A. B., Moroski-Erkul, C. A., McFaline, J. L., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35073 · Cited by 548
The obese adipose tissue microenvironment in cancer development and progression
Quail, D. F., & Dannenberg, A. J. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0126-x · Cited by 542
Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol.
Klauber, N., Parangi, S., Flynn, E. A., Hamel, E., & D’Amato, R. J. (1997) · PubMed · Cited by 524
Protein‐Based Nanomedicine Platforms for Drug Delivery
MaHam, A., Tang, Z., Wu, H., Wang, J., & Lin, Y. (2009) · Small · doi:10.1002/smll.200801602 · Cited by 524
Cancer and Inflammation: An Old Intuition with Rapidly Evolving New Concepts
Trinchieri, G. (2012) · Annual Review of Immunology · doi:10.1146/annurev-immunol-020711-075008 · Cited by 511
Alcohol consumption and ethyl carbamate.
Allen, N. E., Anderson, L. M., Beland, F. A., Bénichou, J., Beral, V., Bloomfield, K., Brooks, P. J., Cai, L., Cho, S., Crabb, D. W., et al. (2010) · PubMed · Cited by 502
Antibody–drug conjugates as novel anti-cancer chemotherapeutics
Peters, C., & Brown, S. (2015) · Bioscience Reports · doi:10.1042/bsr20150089 · Cited by 492
Taxol: an antimitotic agent with a new mechanism of action
Manfredi, J. J., & Horwitz, S. B. (1984) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(84)90025-1 · Cited by 483
Phase I clinical and pharmacokinetic study of taxol.
Wiernik, P. H., Schwartz, E. L., Strauman, J. J., Dutcher, J. P., Lipton, R. B., & Paietta, E. M. (1987) · PubMed · Cited by 455
Tobacco Smoke Promotes Lung Tumorigenesis by Triggering IKKβ- and JNK1-Dependent Inflammation
Takahashi, H., Ogata, H., Nishigaki, R., Broide, D. H., & Karin, M. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.008 · Cited by 438
Cytotoxic studies of paclitaxel (Taxol®) in human tumour cell lines
Liebmann, J., Cook, J., Lipschultz, C., Teague, D., Fisher, J., & Mitchell, J. (1993) · British Journal of Cancer · doi:10.1038/bjc.1993.488 · Cited by 428
Light alcohol drinking and cancer: a meta-analysis
Bagnardi, V., Rota, M., Botteri, E., Tramacere, I., Islami, F., Fedirko, V., Scotti, L., Jenab, M., Turati, F., Pasquali, E., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mds337 · Cited by 424
Interleukin-11 Is the Dominant IL-6 Family Cytokine during Gastrointestinal Tumorigenesis and Can Be Targeted Therapeutically
Putoczki, T. L., Thiem, S., Loving, A., Busuttil, R. A., Wilson, N. J., Ziegler, P. K., Nguyen, P. M., Preaudet, A., Farid, R., Edwards, K. M., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.06.017 · Cited by 421
Paclitaxel: What has been done and the challenges remain ahead
Bernabeu, E., Cagel, M., Lagomarsino, E., Moretton, M., & Chiappetta, D. A. (2017) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2017.05.016 · Cited by 413
Cancer and infection: estimates of the attributable fraction in 1990.
Pisani, P., Parkin, D. M., Muñóz, N., & Ferlay, J. (1997) · PubMed · Cited by 388
Novel Action of Paclitaxel against Cancer Cells: Bystander Effect Mediated by Reactive Oxygen Species
Alexandre, J., Hu, Y., Lu, W., Pelicano, H., & Huang, P. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3914 · Cited by 380
Interleukin-22 protects intestinal stem cells against genotoxic stress
Gronke, K., Hernández, P. P., Zimmermann, J., Klose, C. S. N., Kofoed-Branzk, M., Guendel, F., Witkowski, M., Tizian, C., Amann, L., Schumacher, F., et al. (2019) · Nature · doi:10.1038/s41586-019-0899-7 · Cited by 373
Paclitaxel and Its Evolving Role in the Management of Ovarian Cancer
Kampan, N. C., Madondo, M. T., McNally, O. M., Quinn, M., & Plebanski, M. (2015) · BioMed Research International · doi:10.1155/2015/413076 · Cited by 362
Myeloid Cell-Derived Reactive Oxygen Species Induce Epithelial Mutagenesis
Canli, Ö., Nicolas, A. M., Gupta, J., Finkelmeier, F., Goncharova, O., Pesic, M., Neumann, T., Horst, D., Löwer, M., Sahin, U., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.11.004 · Cited by 359
Development and characterization of a novel Cremophor® EL free liposome-based paclitaxel (LEP-ETU) formulation
Zhang, J. A., Anyarambhatla, G., Ma, L., Ugwu, S., Xuan, T., Sardone, T., & Ahmad, I. (2005) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2004.06.009 · Cited by 334
Alcohol and Cancer: A Statement of the American Society of Clinical Oncology
LoConte, N. K., Brewster, A. M., Kaur, J. S., Merrill, J. K., & Alberg, A. J. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.1155 · Cited by 331
Targeted therapy of cancer with radiolabeled antibodies.
Goldenberg, D. M. (2002) · PubMed · Cited by 318
Nanomedicine applied to translational oncology: A future perspective on cancer treatment
Bregoli, L., Movia, D., Gavigan-Imedio, J. D., Lysaght, J., Reynolds, J., & Prina-Mello, A. (2016) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2015.08.006 · Cited by 296
Chitosan nanoparticles as a promising tool in nanomedicine with particular emphasis on oncological treatment
Sharifi-Rad, J., Quispe, C., Butnariu, M., Rotariu, L. S., Sytar, O., Sestito, S., Rapposelli, S., Akram, M., Iqbal, M., Krishna, A., et al. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02025-4 · Cited by 290
Self-citation
Targeted Therapies for Cancer 2004
Ross, J. S., Schenkein, D. P., Pietrusko, R. G., Rolfe, M., Linette, G. P., Stec, J. J., Stagliano, N. E., Ginsburg, G. S., Symmans, W. F., Pusztai, L., et al. (2004) · American Journal of Clinical Pathology · doi:10.1309/5cwp-u41a-fr1v-ym3f · Cited by 286
Diet, Lifestyle and Cardiovascular Diseases: Linking Pathophysiology to Cardioprotective Effects of Natural Bioactive Compounds
Sharifi-Rad, J., Rodrigues, C. F., Sharopov, F., Docea, A. O., Can Karaca, A., Sharifi-Rad, M., Kahveci Karıncaoglu, D., Gülseren, G., Şenol, E., Demircan, E., et al. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17072326 · Cited by 285
Self-citation
Modifiable and non-modifiable risk factors for pancreatic cancer: A review
Midha, S., Chawla, S., & Garg, P. K. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.07.022 · Cited by 281
Obesity alters the lung myeloid cell landscape to enhance breast cancer metastasis through IL5 and GM-CSF
Quail, D. F., Olson, O. C., Bhardwaj, P., Walsh, L. A., Akkari, L., Quick, M. L., Chen, I.-C., Wendel, N., Ben-Chetrit, N., Walker, J., et al. (2017) · Nature Cell Biology · doi:10.1038/ncb3578 · Cited by 277
Whole-Exome Sequencing Analyses of Inflammatory Bowel Disease−Associated Colorectal Cancers
Robles, A. I., Traverso, G., Zhang, M., Roberts, N. J., Khan, M. A., Joseph, C., Lauwers, G. Y., Selaru, F. M., Popoli, M., Pittman, M. E., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2015.12.036 · Cited by 276
Paclitaxel Through the Ages of Anticancer Therapy: Exploring Its Role in Chemoresistance and Radiation Therapy
Barbuti, A., & Chen, Z.-S. (2015) · Cancers · doi:10.3390/cancers7040897 · Cited by 269
Synergistic Effects of Plant Derivatives and Conventional Chemotherapeutic Agents: An Update on the Cancer Perspective
Pezzani, R., Salehi, B., Vitalini, S., Iriti, M., Zuñiga, F., Sharifi-Rad, J., Martorell, M., & Martins, N. (2019) · Medicina · doi:10.3390/medicina55040110 · Cited by 264
Self-citation
Tumor Promotion via Injury- and Death-Induced Inflammation
Kuraishy, A., Karin, M., & Grivennikov, S. I. (2011) · Immunity · doi:10.1016/j.immuni.2011.09.006 · Cited by 261
Alcohol consumption and ethyl carbamate.
(2010) · PubMed Central · Cited by 261
Dermatological adverse events with taxane chemotherapy
Sibaud, V., Lebœuf, N. R., Roche, H., Belum, V. R., Gladieff, L., Deslandres, M., Montastruc, M., Eche, A., Vigarios, E., Dalenc, F., et al. (2016) · European Journal of Dermatology · doi:10.1684/ejd.2016.2833 · Cited by 257
Alcohol-Attributable Cancer Deaths and Years of Potential Life Lost in the United States
Nelson, D. E., Jarman, D. W., Rehm, J., Greenfield, T. K., Rey, G., Kerr, W. C., Miller, P., Shield, K. D., Ye, Y., & Naimi, T. S. (2013) · American Journal of Public Health · doi:10.2105/ajph.2012.301199 · Cited by 249
Physical and Chemical Strategies for Therapeutic Delivery by Using Polymeric Nanoparticles
Morachis, J. M., Mahmoud, E. A., & Almutairi, A. (2012) · Pharmacological Reviews · doi:10.1124/pr.111.005363 · Cited by 238
Characterization of the Taxol Binding Site on the Microtubule
Rao, S., Orr, G. A., Chaudhary, A. G., Kingston, D. G. I., & Horwitz, S. B. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.35.20235 · Cited by 235
Docetaxel: A Review of its Use in Metastatic Breast Cancer
Lyseng-Williamson, K. A., & Fenton, C. (2005) · Drugs · doi:10.2165/00003495-200565170-00007 · Cited by 225
Gene Therapy in Cancer Treatment: Why Go Nano?
Roma-Rodrigues, C., Rivas-García, L., Baptista, P. V., & Fernandes, A. R. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12030233 · Cited by 220
Trabectedin, a drug acting on both cancer cells and the tumour microenvironment
D’Incalci, M., Badri, N., Galmarini, C. M., & Allavena, P. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.149 · Cited by 218
Enhancing Triple Negative Breast Cancer Immunotherapy by ICG‐Templated Self‐Assembly of Paclitaxel Nanoparticles
Feng, B., Niu, Z., Hou, B., Zhou, L., Li, Y., & Yu, H. (2020) · Advanced Functional Materials · doi:10.1002/adfm.201906605 · Cited by 215
Guidebook to the Cytoskeletal and Motor Proteins
(1999) · doi:10.1093/oso/9780198599579.001.0001 · Cited by 211
Microtubule nucleation: γ-tubulin and beyond
Wiese, C., & Zheng, Y. (2006) · Journal of Cell Science · doi:10.1242/jcs.03226 · Cited by 199
NK cell self tolerance, responsiveness and missing self recognition
Shifrin, N., Raulet, D. H., & Ardolino, M. (2014) · Seminars in Immunology · doi:10.1016/j.smim.2014.02.007 · Cited by 197
Preclinical development of drug delivery systems for paclitaxel-based cancer chemotherapy
Wang, F., Porter, M., Konstantopoulos, A., Zhang, P., & Cui, H. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.09.026 · Cited by 196
Curcumin’s Nanomedicine Formulations for Therapeutic Application in Neurological Diseases
Salehi, B., Calina, D., Docea, A., Koirala, N., Aryal, S., Lombardo, D., Pasqua, L., Taheri, Y., Marina Salgado Castillo, C., Martorell, M., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9020430 · Cited by 196
Self-citation
Joint analysis of three genome-wide association studies of esophageal squamous cell carcinoma in Chinese populations
Wu, C., Wang, Z., Song, X., Feng, X.-S., Abnet, C. C., He, J., Hu, N., Zuo, X.-B., Tan, W., Zhan, Q., et al. (2014) · Nature Genetics · doi:10.1038/ng.3064 · Cited by 188
Problems of Delivery of Monoclonal Antibodies: Pharmaceutical and Pharmacokinetic Solutions
Reilly, R. M., Sandhu, J., Alvarez-Diez, T. M., Gallinger, S., Kirsh, J., & Stern, H. (1995) · Clinical Pharmacokinetics · doi:10.2165/00003088-199528020-00004 · Cited by 187
Classification of anticancer drugs—a new system based on therapeutic targets
Espinosa, E., Zamora, P., Feliu, J., & González Barón, M. (2003) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(03)00116-6 · Cited by 185
Alendronate coated poly-lactic-co-glycolic acid (PLGA) nanoparticles for active targeting of metastatic breast cancer
Thamake, S. I., Raut, S. L., Gryczynski, Z., Ranjan, A. P., & Vishwanatha, J. K. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.06.026 · Cited by 182
RAE1 Ligands for the NKG2D Receptor Are Regulated by STING-Dependent DNA Sensor Pathways in Lymphoma
Lam, A. R., Le Bert, N., Ho, S. S. W., Shen, Y. J., Tang, M. L. F., Xiong, G. M., Croxford, J. L., Koo, C. X., Ishii, K. J., Akira, S., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1703 · Cited by 179
Stable PEG-coated silver nanoparticles – A comprehensive toxicological profile
Pinzaru, I., Coricovac, D., Dehelean, C., Moacă, E.-A., Mioc, M., Baderca, F., Sizemore, I., Brittle, S., Marti, D., Calina, C. D., et al. (2018) · Food and Chemical Toxicology · doi:10.1016/j.fct.2017.11.051 · Cited by 177
Human papilloma virus: Apprehending the link with carcinogenesis and unveiling new research avenues (Review)
Boda, D., Docea, A., Calina, D., Ilie, M., Caruntu, C., Zurac, S., Neagu, M., Constantin, C., Branisteanu, D., Voiculescu, V., et al. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4256 · Cited by 176
Self-citation
Paclitaxel (Taxol): An Inhibitor of Angiogenesis in a Highly Vascularized Transgenic Breast Cancer
Lau, D. H., Xue, L., Young, L. J. T., Burke, P. A., & Cheung, A. (1999) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.1999.14.31 · Cited by 172
Recent Advances in the Chemistry of Taxol
Kingston, D. G. I. (2000) · Journal of Natural Products · doi:10.1021/np000064n · Cited by 172
Taxol: The chemistry and structure-activity relationships of a novel anticancer agent
Kingston, D. G. I. (1994) · Trends in Biotechnology · doi:10.1016/0167-7799(94)90120-1 · Cited by 169
Brassinin inhibits STAT3 signaling pathway through modulation of PIAS-3 and SOCS-3 expression and sensitizes human lung cancer xenograft in nude mice to paclitaxel
Lee, J. H., Kim, C., Sethi, G., & Ahn, K. S. (2015) · Oncotarget · doi:10.18632/oncotarget.3443 · Cited by 162
Plant-Derived Bioactives in Oral Mucosal Lesions: A Key Emphasis to Curcumin, Lycopene, Chamomile, Aloe vera, Green Tea and Coffee Properties
Salehi, B., López‐Jornet, P., Pons-Fuster, E., Călina, D. C., Sharifi‐Rad, M., Ramírez‐Alarcón, K., Forman, K., Fernández, M., Martorell, M., Setzer, W. N., et al. (2019) · Biomolecules · doi:10.3390/biom9030106 · Cited by 160
Self-citation
Paclitaxel enhances early dendritic cell maturation and function through TLR4 signaling in mice
Pfannenstiel, L. W., Lam, S. S. K., Emens, L. A., Jaffee, E. M., & Armstrong, T. D. (2010) · Cellular Immunology · doi:10.1016/j.cellimm.2010.03.001 · Cited by 159
The role of MAP4 expression in the sensitivity to paclitaxel and resistance to vinca alkaloids in p53 mutant cells
Zhang, C. C., Yang, J.-M., White, E., Murphy, M., Levine, A., & Hait, W. N. (1998) · Oncogene · doi:10.1038/sj.onc.1201658 · Cited by 159
Ultra-thermostable RNA nanoparticles for solubilizing and high-yield loading of paclitaxel for breast cancer therapy
Guo, S., Vieweger, M., Zhang, K., Yin, H., Wang, H., Li, X., Li, S., Hu, S., Sparreboom, A., Evers, B. M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14780-5 · Cited by 159
The minus end in sight
Dammermann, A., Desai, A. B., & Oegema, K. (2003) · Current Biology · doi:10.1016/s0960-9822(03)00530-x · Cited by 158
Cationic solid lipid nanoparticles for co-delivery of paclitaxel and siRNA
Yu, Y. H., Kim, E. J., Park, D. E., Shim, G., Lee, S. B., Kim, Y. B., Kim, C., & Oh, Y. (2011) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2011.11.002 · Cited by 154
Mitophagy in Intestinal Epithelial Cells Triggers Adaptive Immunity during Tumorigenesis
Ziegler, P. K., Bollrath, J., Pallangyo, C. K., Matsutani, T., Canli, Ö., Oliveira, T. D., Diamanti, M. A., Müller, N., Gamrekelashvili, J., Putoczki, T. L., et al. (2018) · Cell · doi:10.1016/j.cell.2018.05.028 · Cited by 153
Paclitaxel: new uses for an old drug
Dong, Z., Zhang, D., Yang, R., & Wang, S. (2014) · Drug Design Development and Therapy · doi:10.2147/dddt.s56801 · Cited by 149
Smart Targeting To Improve Cancer Therapeutics
Morales‐Cruz, M., Delgado, Y., Castillo, B., Figueroa, C. M., Molina, A., Torres, A., Milián, M., & Griebenow, K. H. (2019) · Drug Design Development and Therapy · doi:10.2147/dddt.s219489 · Cited by 148
Properties, Engineering and Applications of Lipid-Based Nanoparticle Drug-Delivery Systems: Current Research and Advances
Buse, J. D., & El‐Aneed, A. (2010) · Nanomedicine · doi:10.2217/nnm.10.107 · Cited by 147
Mechanism of taxane neurotoxicity
Hagiwara, H., & Sunada, Y. (2004) · Breast Cancer · doi:10.1007/bf02968008 · Cited by 139
Integrating Nanotechnology into Cancer Care
Grodzinski, P. A., Kircher, M. F., Goldberg, M. S., & Gabizón, A. (2019) · ACS Nano · doi:10.1021/acsnano.9b04266 · Cited by 137
Nanotechnology platforms for cancer immunotherapy
Yang, Z., Ma, Y., Hai, Z., Yuan, Y., & Kim, B. Y. S. (2019) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1590 · Cited by 134
The shape of things to come: Structural and synthetic studies of taxol and related compounds
Kingston, D. G. I. (2006) · Phytochemistry · doi:10.1016/j.phytochem.2006.11.009 · Cited by 132
Paclitaxel-Dependent Cell Lines Reveal a Novel Drug Activity
Ganguly, A., Yang, H., & Cabral, F. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0552 · Cited by 130
Are Racial Disparities in Pancreatic Cancer Explained by Smoking and Overweight/Obesity?
Arnold, L. D., Patel, A. V., Yan, Y., Jacobs, E. J., Thun, M. J., Calle, E. E., & Colditz, G. A. (2009) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-09-0080 · Cited by 127
Paclitaxel dimers assembling nanomedicines for treatment of cervix carcinoma
Pei, Q., Hu, X., Liu, S., Li, Y., Xie, Z., & Jing, X. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.03.391 · Cited by 126
Paclitaxel-loaded PCL–TPGS nanoparticles: In vitro and in vivo performance compared with Abraxane®
Bernabeu, E., Helguera, G. F., Legaspi, M. J., González, L., Höcht, C., Taira, C. A., & Chiappetta, D. A. (2013) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2013.07.036 · Cited by 125
Quantitative Effect of Gender, Age, Liver Function, and Body Size on the Population Pharmacokinetics of Paclitaxel in Patients with Solid Tumors
Joerger, M., Huitema, A. D. R., van den Bongard, H. J. G. D., Schellens, J. H. M., & Beijnen, J. H. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2069 · Cited by 120
Liver Cancer and Alcohol
Grewal, P., & Viswanathen, V. A. (2012) · Clinics in Liver Disease · doi:10.1016/j.cld.2012.08.011 · Cited by 119
Multidrug Resistance: Can New Drugs Help Chemotherapy Score Against Cancer?
Goldman, B. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.4.255 · Cited by 118
Mitochondria-targeting nanomedicine self-assembled from GSH-responsive paclitaxel-ss-berberine conjugate for synergetic cancer treatment with enhanced cytotoxicity
Cheng, Y., & Ji, Y. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.12.011 · Cited by 116
Attributable Causes of Liver Cancer Mortality and Incidence in China
Fan, J., Wang, J.-B., Jiang, Y. L., Xiang, W., Liang, H., Wei, W., Qiao, Y., & Boffetta, P. (2013) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2013.14.12.7251 · Cited by 115
Paclitaxel loaded vitamin E-TPGS nanoparticles for cancer therapy
Gorain, B., Choudhury, H., Pandey, M., & Kesharwani, P. (2018) · Materials Science and Engineering C · doi:10.1016/j.msec.2018.05.054 · Cited by 113
The Effect of Silver Nanoparticles on Antioxidant/Pro-Oxidant Balance in a Murine Model
Docea, A. O., Calina, D., Buga, A. M., Zlatian, O., Paoliello, M. M. B., Mogosanu, G. D., Streba, C. T., Popescu, E. L., Stoica, A. E., Bîrcă, A. C., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21041233 · Cited by 111
Self-citation
Oxymatrine Attenuates Tumor Growth and Deactivates STAT5 Signaling in a Lung Cancer Xenograft Model
Jung, Y. Y., Shanmugam, M. K., Narula, A. S., Kim, C., Lee, J. H., Namjoshi, O. A., Blough, B. E., Sethi, G., & Ahn, K. S. (2019) · Cancers · doi:10.3390/cancers11010049 · Cited by 110
Survival of patients with skin melanoma in Europe increases further: Results of the EUROCARE-5 study
Crocetti, E., Mallone, S., Robsahm, T. E., Gavin, A., Agius, D., Ardanáz, E., López, M. C., Innos, K., Minicozzi, P., Borgognoni, L., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.07.039 · Cited by 109
Folate-Decorated Hybrid Polymeric Nanoparticles for Chemically and Physically Combined Paclitaxel Loading and Targeted Delivery
Wang, J., Liu, W., Tu, Q., Wang, J., Song, N., Zhang, Y., Nie, N., & Wang, J. (2010) · Biomacromolecules · doi:10.1021/bm101206g · Cited by 106
Avocado–Soybean Unsaponifiables: A Panoply of Potentialities to Be Exploited
Salehi, B., Rescigno, A., Dettori, T., Călina, D. C., Docea, A. O., Singh, L., Cebeci, F., Özçelik, B., Bhia, M., Beirami, A. D., et al. (2020) · Biomolecules · doi:10.3390/biom10010130 · Cited by 106
Self-citation
Therapeutic Applications of Curcumin Nanomedicine Formulations in Cardiovascular Diseases
Salehi, B., Prado-Audelo, M. L. D., Cortés, H., Leyva‐Gómez, G., Stojanović-Radić, Z. Z., Singh, Y. D., Patra, J. K., Das, G., Martins, N. A., Martorell, M., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9030746 · Cited by 105
Self-citation
Recent Advancements of Nanomedicine towards Antiangiogenic Therapy in Cancer
Mukherjee, A., Madamsetty, V. S., Paul, M. K., & Mukherjee, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21020455 · Cited by 103
Applications of Nanosized-Lipid-Based Drug Delivery Systems in Wound Care
Matei, A.-M., Căruntu, C., Tampa, M. Ş., Georgescu, S. R., Matei, C., Constantin, M. M., Constantin, T. V., Călina, D. C., Ciubotaru, D. A., Bădărău, I. A., et al. (2021) · Applied Sciences · doi:10.3390/app11114915 · Cited by 103
Magnetic targeting of paclitaxel-loaded poly(lactic-co-glycolic acid)-based nanoparticles for the treatment of glioblastoma
Ganipineni, L. P., Učakar, B., Joudiou, N., Bianco, J. I., Danhier, P., Zhao, M., Bastiancich, C., Gallez, B., Danhier, F., & Véronique Préat, A. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s165184 · Cited by 100
Paclitaxel-loaded redox-sensitive nanoparticles based on hyaluronic acid-vitamin E succinate conjugates for improved lung cancer treatment
Song, Y. N., Cai, H., Yin, T., Huo, M., Ma, P., Zhou, J., & Lai, W. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s155383 · Cited by 98
Paclitaxel and the dietary flavonoid fisetin: a synergistic combination that induces mitotic catastrophe and autophagic cell death in A549 non-small cell lung cancer cells
Klimaszewska‐Wiśniewska, A., Hałas‐Wiśniewska, M., Tadrowski, T., Gagat, M., Grzanka, D., & Grzanka, A. (2016) · Cancer Cell International · doi:10.1186/s12935-016-0288-3 · Cited by 94
Paclitaxel combined with inhibitors of glucose and hydroperoxide metabolism enhances breast cancer cell killing via H2O2-mediated oxidative stress
Hadzic, T., Aykin‐Burns, N., Zhu, Y., Coleman, M. C., Leick, K. M., Jacobson, G., & Spitz, D. R. (2010) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2010.01.018 · Cited by 92
Inflammation-Related IL1β/IL1R Signaling Promotes the Development of Asbestos-Induced Malignant Mesothelioma
Kadariya, Y., Menges, C. W., Talarchek, J. N., Cai, K. Q., Klein–Szanto, A. J., Pietrofesa, R. A., Christofidou‐Solomidou, M., Cheung, M., Mossman, B. T., Shukla, A., et al. (2016) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-15-0347 · Cited by 92
Veronica Plants—Drifting from Farm to Traditional Healing, Food Application, and Phytopharmacology
Salehi, B., Shetty, M. S., Kumar, N. V. A., Živković, J., Călina, D. C., Docea, A. O., Yazdi, S. E., Kılıç, C. S., Goloshvili, T., Nicola, S., et al. (2019) · Molecules · doi:10.3390/molecules24132454 · Cited by 91
Self-citation
Anticancer effects of gemcitabine are enhanced by co-administered iRGD peptide in murine pancreatic cancer models that overexpressed neuropilin-1
Akashi, Y., Oda, T., Ohara, Y., Miyamoto, R., Kurokawa, T., Hashimoto, S., Enomoto, T., Yamada, K., Satake, M., & Ohkohchi, N. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.49 · Cited by 90
Synthesis and Evaluation of Paclitaxel-Loaded Gold Nanoparticles for Tumor-Targeted Drug Delivery
Paciotti, G. F., Zhao, J., Cao, S., Brodie, P. J., Tamarkin, L., Huhta, M. S., Myer, L. D., Friedman, J., & Kingston, D. G. I. (2016) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.6b00405 · Cited by 89
Improving anti-tumor activity with polymeric micelles entrapping paclitaxel in pulmonary carcinoma
Gong, C., Xie, Y., Wu, Q., Wang, Y., Deng, S., Xiong, D., Liu, L., Xiang, M., Qian, Z., & Wei, Y. (2012) · Nanoscale · doi:10.1039/c2nr31517c · Cited by 87
A phase II trial of bryostatin 1 in the treatment of metastatic colorectal cancer.
Zonder, J. A., Shields, A. F., Zalupski, M. M., Chaplen, R., Heilbrun, L. K., Arlauskas, P., & Philip, P. A. (2001) · PubMed · Cited by 82
Rapamycin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and induction of apoptosis
Shafer, A., Zhou, C., Gehrig, P. A., Boggess, J. F., & Bae-Jump, V. L. (2009) · International Journal of Cancer · doi:10.1002/ijc.24837 · Cited by 79
From taxol to taxol®: The changing identities and ownership of an anti-cancer drug
Walsh, V., & Goodman, J. (2002) · Medical Anthropology · doi:10.1080/01459740214074 · Cited by 79
Epidemiologic and etiologic factors of pancreatic cancer
Lowenfels, A. B., & Maisonneuve, P. (2002) · Hematology/Oncology Clinics of North America · doi:10.1016/s0889-8588(01)00003-x · Cited by 79
Cancer chemotherapy, biodiversity, public and private property: The case of the anti-cancer drug Taxol
Walsh, V., & Goodman, J. (1999) · Social Science & Medicine · doi:10.1016/s0277-9536(99)00161-6 · Cited by 78
Redirecting Transport of Nanoparticle Albumin-Bound Paclitaxel to Macrophages Enhances Therapeutic Efficacy against Liver Metastases
Tanei, T., Leonard, F., Liu, X., Alexander, J. F., Saito, Y., Mauro Ferrari, B., Godin, B., & Yokoi, K. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1576 · Cited by 78
Paclitaxel (Taxol) upregulates expression of functional interleukin-6 in human ovarian cancer cells through multiple signaling pathways
Th, W., Chan, Y.-H., Chen, C., Kung, W.-H., Lee, Y.-S., Wang, S., Chang, T.-C., & Wang, H. (2006) · Oncogene · doi:10.1038/sj.onc.1209498 · Cited by 77
The Winning Formulation: The Development of Paclitaxel in Pancreatic Cancer
Ma, W. W., & Hidalgo, M. M. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1356 · Cited by 77
Potentiation of Taxol Efficacy by Discodermolide in Ovarian Carcinoma Xenograft-Bearing Mice
Huang, G. S., Lopez-Barcons, L. A., Freeze, B. S., Smith, A. B., Goldberg, G. L., Horwitz, S. B., & McDaid, H. M. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0229 · Cited by 76
Plant Toxin-Based Immunotoxins for Cancer Therapy: A Short Overview
Polito, L., Djemil, A., & Bortolotti, M. (2016) · Biomedicines · doi:10.3390/biomedicines4020012 · Cited by 75 · cited 1×
“The linker should be stable in blood but cleavable within the target cells by specific enzymatic or chemical degradation, thus, releasing the drug in an active form that can kill the cancer cell [29].”
BackgroundSelf-citation
ABO blood type and the risk of cancer – Findings from the Shanghai Cohort Study
Huang, J. Y., Wang, R., Gao, Y., & Yuan, J. (2017) · PLoS ONE · doi:10.1371/journal.pone.0184295 · Cited by 75
Cycloastragenol can negate constitutive STAT3 activation and promote paclitaxel-induced apoptosis in human gastric cancer cells
Hwang, S. T., Kim, C., Lee, J. H., Chinnathambi, A., Alharbi, S. A., Shair, O. H. M., Sethi, G., & Ahn, K. S. (2019) · Phytomedicine · doi:10.1016/j.phymed.2019.152907 · Cited by 75
A phase 2 pilot trial of low‐dose, continuous infusion, or “metronomic” paclitaxel and oral celecoxib in patients with metastatic melanoma
Bhatt, R. S., Merchan, J. R., Parker, R. A., Wu, H., Zhang, L., Seery, V. J., Heymach, J. V., Atkins, M. B., McDermott, D. F., & Sukhatme, V. P. (2010) · Cancer · doi:10.1002/cncr.24902 · Cited by 72
Catalytic Properties of Pd Modified Cu/SAPO‐34 for NOx Removal from Diesel Engine
Wang, J. C., Qiao, H., Han, L., Zuo, Y. Q., Chang, L. P., Bao, W. R., & Feng, G. (2013) · Journal of Nanomaterials · doi:10.1155/2013/625739 · Cited by 72
Intraperitoneal administration of cisplatin via an in situ cross-linkable hyaluronic acid-based hydrogel for peritoneal dissemination of gastric cancer
Emoto, S., Yamaguchi, H., Kamei, T., et al. (2013) · Surgery Today · doi:10.1007/s00595-013-0674-6 · Cited by 70
Multidrug resistance-related phenotype and apoptosis-related protein expression in ovarian serous carcinomas
Yakirevich, E., Sabo, E., Naroditsky, I., Sova, Y., Lavie, O., & Resnick, M. B. (2005) · Gynecologic Oncology · doi:10.1016/j.ygyno.2005.08.050 · Cited by 68
Physical‐, chemical‐, and biological‐responsive nanomedicine for cancer therapy
Liao, J., Jia, Y., Wu, Y., Shi, K., Yang, D., Li, P., & Qian, Z. (2020) · WIREs Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1581 · Cited by 67
Pharmacokinetics and tissue distribution of intraperitoneal paclitaxel with different carrier solutions
Mohamed, F., Marchettini, P., Stuart, O. A., & Sugarbaker, P. H. (2003) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-003-0680-2 · Cited by 67
Drug combination using an injectable nanomedicine hydrogel for glioblastoma treatment
Bastiancich, C., Bozzato, E., Luyten, U., Danhier, F., Bastiat, G., & Véronique Préat, A. (2019) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2019.01.042 · Cited by 67
Histochemical and immunohistochemical evidence of tumor heterogeneity in colorectal cancer.
Zlatian, O. M., Comanescu, M. V., Roşu, A. F., Roşu, L., Cruce, M., Găman, A. E., Călina, C. D., & Sfredel, V. (2015) · PubMed · Cited by 65
Pharmacogenomics — Teaching Old Drugs New Tricks
Weinstein, J. N. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011093431910 · Cited by 65
Loss of p53 enhances the induction of colitis-associated neoplasia by dextran sulfate sodium
Chang, W., Coudry, R. A., Clapper, M. L., Zhang, X., Williams, K.-L., Spittle, C., Li, T., & Cooper, H. S. (2007) · Carcinogenesis · doi:10.1093/carcin/bgm134 · Cited by 65
Advances in paclitaxel combinations for treating cervical cancer
Corte, L. D., Barra, F., Foreste, V., Giampaolino, P., Evangelisti, G., Ferrero, S., & Bifulco, G. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1724284 · Cited by 60
Paclitaxel and other taxanes in hazelnut
Hoffman, A. M., & Shahidi, F. (2008) · Journal of Functional Foods · doi:10.1016/j.jff.2008.09.004 · Cited by 58
Application of paclitaxel in low non-cytotoxic doses supports vaccination with melanoma antigens in normal mice
Sevko, A., Kremer, V., Falk, C. S., Umansky, L., Shurin, M. R., Shurin, G. V., & Umansky, V. (2012) · Journal of Immunotoxicology · doi:10.3109/1547691x.2012.655343 · Cited by 58
Co-delivery of dual-drugs with nanoparticle to overcome multidrug resistance
Sun, Y., Chen, K., Zhang, A., Liu, F., Hu, J., Zhong, X. Y., & Xie, J. (2016) · European Journal of BioMedical Research · doi:10.18088/ejbmr.2.2.2016.pp12-18 · Cited by 53
Combination of Paclitaxel and R-flurbiprofen loaded PLGA nanoparticles suppresses glioblastoma growth on systemic administration
Caban-Toktas, S., Şahin, A., Lüle, S., Esendağlı, G., Vural, İ., Oğuz, K. K., Söylemezoğlu, F., Mut, M., Dalkara, T., Khan, M. A., et al. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2020.119076 · Cited by 52
Artificial Intelligence and Related Technologies Enabled Nanomedicine for Advanced Cancer Treatment
Wilson, B., & Geetha, K. M. (2020) · Nanomedicine · doi:10.2217/nnm-2019-0366 · Cited by 51
Selective targeting of breast cancer cells through ROS-mediated mechanisms potentiates the lethality of paclitaxel by a novel diterpene, gelomulide K
Yang, J., Lu, M., Lee, C.-L., Chen, G., Lin, Y.-Y., Chang, F., & Wu, Y. (2011) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.05.012 · Cited by 49
Racial Differences in Pancreatic Cancer: Comparison of Survival and Histologic Types of Pancreatic Carcinoma in Asians, Blacks, and Whites in the United States
Longnecker, D. S., Karagas, M. R., Tosteson, T. D., & Mott, L. A. (2000) · Pancreas · doi:10.1097/00006676-200011000-00003 · Cited by 48
Advanced nanoscale carrier-based approaches to overcome biopharmaceutical issues associated with anticancer drug ‘Etoposide’
Choudhury, H., Maheshwari, R., Pandey, M., Tekade, M., Gorain, B., & Tekade, R. K. (2019) · Materials Science and Engineering C · doi:10.1016/j.msec.2019.110275 · Cited by 48
Cytotoxic and apoptogenic properties of Dracocephalum Kotschyi aerial part different fractions on calu-6 and mehr-80 lung cancer cell lines
Sani, T. A., Mohammadpour, E., Mohammadi, A., Memariani, T., Yazdi, M. V., Rezaee, R., Călina, D. C., Docea, A. O., Γούμενου, Μ., Etemad, L., et al. (2017) · Cited by 46
Nanomaterials innovation as an enabler for effective cancer interventions
Russell, L. M., Liu, C. H., & Grodzinski, P. A. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.119926 · Cited by 46
Therapeutic Potential of Neoechinulins and Their Derivatives: An Overview of the Molecular Mechanisms Behind Pharmacological Activities
Sharifi-Rad, J., Bahukhandi, A., Dhyani, P., Sati, P., Capanoglu, E., Docea, A. O., Al-Harrasi, A., Dey, A., & Calina, D. (2021) · Frontiers in Nutrition · doi:10.3389/fnut.2021.664197 · Cited by 43 · cited 1×
“frequently than normal cells, and for this reason, they can be more affected than healthy tissues [16].”
Background
A diverse induction of apoptosis by trabectedin in MCF-7 (HER2−/ER+) and MDA-MB-453 (HER2+/ER−) breast cancer cells
Atmaca, H., Bozkurt, E., Uzunoğlu, S., Uslu, R., & Karaca, B. (2013) · Toxicology Letters · doi:10.1016/j.toxlet.2013.06.213 · Cited by 43
Nanoassemblies from amphiphilic cytarabine prodrug for leukemia targeted therapy
Liu, J., Zhao, D., He, W., Zhang, H., Li, Z., & Luan, Y. (2016) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2016.10.041 · Cited by 42
Overcoming tumor cell chemoresistance using nanoparticles: lysosomes are beneficial for (stearoyl) gemcitabine-incorporated solid lipid nanoparticles
Chen, Z., Zheng, Y., Shi, Y.-X., & Cui, Z. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s149196 · Cited by 42
Emerging nanomedicine-based strategies for preventing metastasis of pancreatic cancer
Li, Y., Wu, J., Wang, J., & Xiang, D. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.01.041 · Cited by 42
Immunosurveillance of senescent cancer cells by natural killer cells
Iannello, A., & Raulet, D. H. (2014) · OncoImmunology · doi:10.4161/onci.27616 · Cited by 41
Immunohistochemical expression of TGF beta (TGF-β), TGF beta receptor 1 (TGFBR1), and Ki67 in intestinal variant of gastric adenocarcinomas.
Docea, A. O., Mitruț, P., Grigore, D., Pirici, D., Călina, D. C., & Gofiţă, E. (2012) · PubMed · Cited by 38
In vitro and in vivo targeting effect of folate decorated paclitaxel loaded PLA–TPGS nanoparticles
Ha, P. T., Nam, N. H., Quang, B. T., Sơn, H. A., Toàn, N. L., & Quang, D. T. (2015) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2015.02.002 · Cited by 37
Paclitaxel-Loaded TPGS-b-PCL Nanoparticles: In Vitro Cytotoxicity and Cellular Uptake in MCF-7 and MDA-MB-231 Cells versus mPEG-b-PCL Nanoparticles and Abraxane®
Bernabeu, E., González, L., Legaspi, M. J., Moretton, M. A., & Chiappetta, D. A. (2015) · Journal of Nanoscience and Nanotechnology · doi:10.1166/jnn.2016.10739 · Cited by 37
Harnessing the immune system for the treatment of breast cancer
Jiang, X. (2014) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b1300264 · Cited by 36
Non-invasive imaging techniques for the in�vivo diagnosis of Bowen's disease: Three case reports
Ianoși, S. L., Batani, A., Ilie, M. A., Tampa, M. Ş., Georgescu, S. R., Zurac, S., Boda, D., Ianoşi, N. G., Neagoe, D. C., Călina, D. C., et al. (2019) · Oncology Letters · doi:10.3892/ol.2019.10079 · Cited by 35
Bioresponsive albumin-conjugated paclitaxel prodrugs for cancer therapy
Yang, J., Lv, Q., Wei, W., Yang, Z., Dong, J., Zhang, R., Kan, Q., He, Z., & Xu, Y. (2018) · Drug Delivery · doi:10.1080/10717544.2018.1451935 · Cited by 34

Natural Products as Anticancer Agents: Current Status and Future Perspectives
Naeem, A., Hu, P., Yang, M., Zhang, J., Liu, Y., Zhu, W., & Zheng, Q. (2022) · Molecules · doi:10.3390/molecules27238367 · Cited by 607
Anticancer potential of alkaloids: A key emphasis to colchicine, vinblastine, vincristine, vindesine, vinorelbine and vincamine
Dhyani, P., Quispe, C., Sharma, E., Bahukhandi, A., Sati, P., Attri, D. C., Szopa, A., Sharifi-Rad, J., Docea, A. O., Mardare, I., et al. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02624-9 · Cited by 483
Self-citation
Diosgenin: An Updated Pharmacological Review and Therapeutic Perspectives
Semwal, P., Painuli, S., Abu-Izneid, T., Rauf, A., Sharma, A., Daştan, S. D., Kumar, M., Alshehri, M. M., Taheri, Y., Das, R., et al. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/1035441 · Cited by 195
Self-citation
Anticancer Potential and Other Pharmacological Properties of Prunus armeniaca L.: An Updated Overview
Kitic, D., Miladinovic, B., Randjelovic, M., Szopa, A., Sharifi-Rad, J., Calina, D., & Seidel, V. (2022) · Plants · doi:10.3390/plants11141885 · Cited by 96
Self-citation
Myricetin: Targeting signaling networks in cancer and its implication in chemotherapy
Javed, Z., Khan, K., Herrera-Bravo, J., Naeem, S., Iqbal, M. J., Raza, Q., Sadia, H., Raza, S., Bhinder, M., Calina, D., et al. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02663-2 · Cited by 93
Self-citation

See all 298

Authors: Sharifi-Rad, J., Quispe, C., Patra, J. K., Singh, Y. D., Panda, M. K., Das, G., Adetunji, C. O., Michael, O. S., Sytar, O., Polito, L., Živković, J., Cruz-Martins, N., Klimek-Szczykutowicz, M., Ekiert, H., Choudhary, M. I., Ayatollahi, S. A., Tynybekov, B., Kobarfard, F., Muntean, A. C., Grozea, I., Daştan, S. D., Butnariu, M., Szopa, A., & Calina, D.
Venue: Oxidative Medicine and Cellular Longevity
Publisher: Wiley
Published: 2021-01
Volume: 2021
Issue: 1
Pages: 3687700-3687700
ISSN: 1942-0994 (ISSN-L)
1942-0900
DOI: 10.1155/2021/3687700
OpenAlex: W3205724362
Cited by: 298
References: 217
FWCI: 9.24
Type: journal article
Language: en
Open access: hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

Paclitaxel: Application in Modern Oncology and Nanomedicine‐Based Cancer Therapy

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Self-check

Citations

Cites

Cited by

Metadata

Record

About these checks

Data sources